I see the local lab thing as a potential selling point from the standpoint of obtaining quicker results, which is attractive to the impatient many (like me). However, the surprisingly long time frame until US approval is even more of a looming negative at this point in time.
MYNZ- Down 40% to about $1.23 a share after announcing pricing of $5.0 million of a registered direct offering at $1.20 a share. This company has a diagnostic test for sale in Europe now *with disappointing sales) and have some interesting mRNA second gen diagnostic test technology for colon cancer but their financial condition isn't so good.
Their IPO was at $5 in Oct 2021 ( got $10 million then) and then did a raise Jan 2022 at $23.75/share raising $40 million. Right now they have $11 million in cash left , had a loss of $20million in the last 12 months. Raising only $5million at $1.20 is far short of what they need to conduct large scale trials in the US or elsewhere for their gen 2 test. Unless somebody makes an offer soon, I think it looks bleak for them.
Market Data 
Markets 
AI
